Our advanced kinase
inhibitors are designed
to address the key
limitations of cancer
therapies.
 
Presentations & Publications
For more information or copies of Deciphera presentations, contact us at 785.830.2100 or info@deciphera.com.

2017

Jun 2017
“Pharmacokinetic-driven phase I study of DCC-2618 a pan-KIT and PDGFR inhibitor in patients (pts) with gastrointestinal stromal tumor (GIST) and other solid tumors.” ASCO 2017 Annual Meeting, Chicago, Il. Abstract# 2515.
Apr 2017
“Translational research in a phase I proof-of-concept study supports that DCC-2618 is a pan-KIT inhibitor.” AACR 2017 Annual Meeting, Washington DC. Abstract# LB-039.

2016

Jan 2016
“Oncogenic BRaf Deletions That Function as Homodimers and Are Sensitive to Inhibition by Raf Dimer Inhibitor LY3009120”, Cancer Discovery 2016; Jan. online.

2015

Aug 2015
“Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.” Mol Cancer Ther. 2015; 14(9):2023-34.

Jul 2015
“Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.” Cancer Cell 2015; 28:384-98.

May 2015
“Discovery of 1‑(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3‑d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells.” J. Medicinal Chemistry 2015; 58, 4165−79.

Apr 2015
“DCC-2618 is a potent inhibitor of wild type and mutant KIT, including refractory Exon 17 D816 KIT mutations.” AACR 106th Annual Meeting, Philadelphia, PA. Cancer Res 75(15 Suppl); Abstract 2690<

Apr 2015
“Altiratinib is a potent inhibitor of TRK kinases and is efficacious in TRK-fusion driven cancer models.” AACR 106th Annual Meeting, Philadelphia, PA. Cancer Res 75(15 Suppl): Abstract 790.

Apr 2015
“Rebastinib potently inhibits function of perivascular TIE2 expressing macrophages in vitro and in vivo.” AACR 106th Annual Meeting, Philadelphia, PA. Cancer Res 75(15 Suppl): Abstract 397.

Apr 2015
“Imaging the tumor microenvironment of metastasis reveals the mechanism of transient blood vessel permeability and tumor cell intravasation.” AACR 106th Annual Meeting, Philadelphia, PA. Cancer Res 75(15 Suppl): Abstract 5125.

Apr 2015
“Mechanisms of transendothelial migration by invasive breast carcinoma cells from patients.” AACR 106th Annual Meeting, Philadelphia, PA. Cancer Res 75(15 Suppl): Abstract 4112.

Apr 2015
“Inhibiting endothelium directed tumor cell streaming by targeting the HGF/c-MET and EGF/CSF-1 signaling pathways.” AACR 106th Annual Meeting, Philadelphia, PA. Cancer Res 75(15 Suppl): Abstract 5091.

2014

Nov 2014
“Altiratinib (DCC-2701): a balanced inhibitor of MET, TIE2, and VEGFR2 kinases that exhibits broad anti-tumor and anti-angiogenic activities.” 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain.

Nov 2014
“The novel c-MET inhibitor altiratinib (DCC-2701) inhibits tumor growth and invasion in a bevacizumab resistant glioblastoma mouse model.” Society for Neuro-Oncology Annual Meeting, Miami, FL. Neuro Oncol 16(suppl 5): v6.

Apr 2014
“Identification of LY3009120 as a pan inhibitor of Raf isoforms and dimer with activity against BRaf or Ras mutant tumor cells and minimal paradoxical activation.” AACR Annual Meeting, San Diego, CA. Cancer Res 74(19 Suppl): Abstract DDT02-02.

Feb 2014
“Rebastinib, a selective TIE2 kinase inhibitor, decreases TIE2-expressing macrophages, reduces metastasis, and increases survival in murine cancer models.” AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment Meeting, San Diego, CA. Cancer Res 75(1 Suppl): Abstract PR01.

Feb 2014
“The specific FMS kinase inhibitor, DCC-3014, durably inhibits FMS kinase in vivo and blocks cancer bone invasiveness.” AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment Meeting, San Diego, CA. Cancer Res 75(1 Suppl): Abstract A53.

2013

Dec 2013
“Rebastinib in combination with paclitaxel ablates TIE2-expressing macrophages, reduces metastasis, and increases survival in the PyMT metastatic breast cancer model.” San Antonio Breast Cancer Symposium, San Antonio, TX 2013

Dec 2013
“Rebastinib in combination with eribulin ablates TIE2-expressing macrophages, reduces metastasis, and increases survival in the PyMT metastatic breast cancer model.” San Antonio Breast Cancer Symposium, San Antonio, TX 2013

Dec 2013
“Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment.” Oncogene, December 2013

Nov 2013
“Use of μCT imaging in the PyMT breast cancer model to monitor lung metastasis development and determine therapeutic benefit in real time.” AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Boston, MA. Mol Cancer Ther November 2013 12; B145

Sep 2013
“Selective FMS Kinase inhibitors for Cancer.” 11th Annual CHI Discovery on Target, Boston, MA 2013

Apr 2013
“Rebastinib and DCC-2701: Targeting of resistance mechanisms in cancer treatment.” 245th National American Chemical Society Symposium, New Orleans, LA 2013

Feb 2013
“Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation.” Leukemia 2012; 27:278-85.

Jan 2013
“Rebastinib, a small molecule TIE2 kinase inhibitor, prevents primary tumor growth and lung metastasis in the PyMT breast cancer model.” AACR Special Conference on Tumor Invasion and Metastasis; San Diego, CA. Cancer Res February 1, 2013 73; B78

2011

Apr 2011
“The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile”, Cancer Research, Volume 71, Issue 9, 3189-95, April 2011

Apr 2011
“Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036”, Cancer Cell, Volume 19, Issue 4, 556-568, April 2011

Jan 2011
“Targeted Inhibition of Multiple Receptor Tyrosine Kinases in Mesothelioma.” Neoplasia, Volume 13, Number 1 , 12-22, January 2011

2010

Oct 2010
“Switch Control Pocket Inhibitors of p38-MAP Kinase. Durable Type II Inhibitors that do not Require Binding into the Canonical ATP Hinge Region”, Bioorg. Med. Chem Letters, Vol 20, Issue 19, 5793-5798, October 2010

Back to Top